As The Going Gets Tough In U.S., Indian Generic Makers Turn To The Land Of The Rising Sun
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Structural shifts in the Japanese pharmaceutical landscape, low generic penetration, a number of patent expiries in the next three years and an increasingly unattractive U.S. market is pushing top Indian drug makers to look at the second-largest market to maintain their growth trajectory
You may also be interested in...
Fujifilm’s Sayonara To Dr. Reddy’s: Deal To Sell Generics In Japan Shelved
A high-profile joint venture between Fujifilm and Dr. Reddy’s to sell generic drugs in Japan has been terminated only two years after an initial MOU.
India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle
MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck
India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle
MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck